Objective: The extent to which increasing age is associated with impairment in cognitive function, termed cognitive aging, may have been overestimated in prior studies. The inclusion of individuals with severe or uncontrolled systemic medical illness or prodromal neurodegenerative disease in normal aging samples is likely to bias estimates toward lower cognitive performance and inflate estimates of variability. Method: Unbiased estimates of cognitive aging in 658 adults aged 60-84, who underwent rigorous screening to ensure their general and cognitive health, were computed. The first study screened the psychometric properties of a battery of neuropsychological tests in order to identify those with optimal properties to evaluate cognitive aging. The second study used the selected tests to compare baseline performance within 5-year age bands from 60 to 84. Results: The first study identified a battery of 12 tests that provided reliable measures of memory, psychomotor speed, attention, and executive function and were appropriate for investigating age-related cognitive changes. The second study observed moderate to large agerelated impairment for performance on tests of complex psychomotor function, category fluency, verbal learning, and verbal and visual memory. No, or only small, age effects were observed for working memory, phonemic fluency, learning of visual information, and reaction time. Conclusions: These data suggested that while increasing age is associated with impairment in cognitive function, this impairment is less severe and is evident only on more complex neuropsychological tests than estimated previously in samples selected using less rigorous criteria to ensure cognitive health.
Introduction
Relationships between increasing age and decreasing sensory acuity, reductions in mobility and strength, and increasing prevalence of systemic illness are well described (Rantakokko, Mänty, & Rantanen, 2013; Melis, Marengoni, Angleman, & Fratiglioni, 2014; Heine & Browning, 2015) . However, there remains uncertainty about the extent to which increasing age is associated with a reduction in cognitive abilities independent of central nervous system (CNS) disease, termed cognitive aging.
Studies of cognitive aging conclude that increasing age is associated with impairment across multiple cognitive domains Lindenberger, 2014) . Cross-sectional comparisons of older adults of different ages indicated that the greatest age-related impairment (e.g.,~1-1.5 standard deviation [SD] ) occurs for psychomotor speed and episodic memory (Schaie, 2005; van Hooren et al., 2007; Salthouse, 2010; Bates & Wolbers, 2014; Bonsang & Dohmen, 2015) . From a neuropsychological perspective, however, the criteria used to define the healthy aging samples used in many studies of cognitive aging have lacked precision and this has limited the extent to which their data reflect true cognitive aging. For example, healthy aging has been defined as the absence of a dementia diagnosis (e.g., Deary, Johnson & Starr, 2010; Brown et al., 2012) , normal scores on brief cognitive screening tools such as the Mini Mental State Examination (MMSE) or Montreal Cognitive Assessment (e.g., Deary et al., 2010; Bates & Wobers, 2014) , self-reports of good health on health questionnaires (e.g., Bates & Wobers, 2014) , or that the individual is community-dwelling (e.g., Gerstorf, Ram, Hoppmann, Willis, & Schaie, 2011) . Although such criteria will likely identify and exclude individuals with severe cognitive impairment or dementia, they are unlikely to exclude those with subtle cognitive impairment or prodromal CNS disease Clouston, Glymour, & Terrera, 2015) . Furthermore, increasing age is associated with increasing prevalence of systemic illnesses, such as cardiovascular, endocrine, immune, or inflammatory disease, which themselves are also associated with subtle impairments in cognition (Bergman, Blomberg, & Almkvist, 2007; Melis et al., 2014) . While some aging studies have used objective measures to determine the health status of their sample (e.g., Gerstorf et al. 2011 extract and code medical data), others rely on self-reported medical history (e.g., Bates & Wobers, 2014) or do not report their methods for determining general health status (e.g., Deary et al., 2010; Brown et al., 2012) . Inclusion of adults with severe or uncontrolled systemic disease in samples used to study healthy aging will likely bias estimates of cognitive change negatively; particularly in older groups where their prevalence increases (Bergman et al., 2007) .
Neuropsychological estimates of healthy aging require more rigorous criteria be applied to exclude individuals with subclinical CNS disease and with severe or uncontrolled systemic illness. For example, the development of robust normative data is based on exclusion of older individuals with subclinical CNS disease through the use of longitudinal study where data for individuals considered to be healthy initially, but who ultimately progress to meet clinical criteria for dementia, are removed from estimates of normal performance (e.g., Sliwinski, Lipton, Buschke, & Stewart, 1996; De Santi et al., 2008; Clark et al., 2016) . Large prospective studies of neurodegenerative disease conducted within a medical context offer an opportunity to apply the robust normative methodology to the development of neuropsychological models of cognitive aging. These studies generally conduct thorough assessments of both physical and neurological health, often over multiple visits, in older individuals who are at risk of the disease of interest (e.g., Roberts et al., 2008; Petersen et al., 2010) . Therefore, classification of older individuals as being cognitively and physically healthy is based on the outcome of rigorous, objective, and repeated assessment. This allows the identification and exclusion of individuals with severe or uncontrolled systemic illness as well as those with subclinical CNS disease.
There is however a limitation in using neuropsychological data from prospective studies of neurodegenerative disease to study the neuropsychology of aging, in that test batteries in such studies are designed primarily to identify cognitive dysfunction relevant to the disease of interest. For example, test batteries used to study the development of Alzheimer's disease (AD) focus on episodic memory whereas those used to study the development of Parkinson's disease (PD) focus mainly on processing speed (Ellis et al., 2009; Weintraub et al., 2015) . Such batteries may therefore not assess cognitive function in a breadth sufficient to understand cognitive aging. They may also contain tests that do not have sufficient sensitivity to cognitive changes in healthy older adults who typically perform at maximum levels (e.g., Agrell & Dehlin, 1998; Jefferson et al., 2007) . The resultant skewed data distributions reduce the reliability of performance scores and hence decrease the sensitivity of tests to discriminate subtle differences in cognition (Storandt & Morris, 2010) . Given these potential limitations, the psychometric properties of data from neuropsychological test batteries used in prospective studies of neurodegenerative disease should be evaluated carefully prior to their application to study cognitive aging.
The aim of this study was to estimate the effect of age on cognition by studying the performance on neuropsychological tests of a large group of older adults whose physical and mental health had been assured from extensive repeated assessment as part of their participation in a large prospective study of the development and evolution of AD. First, an analysis of the psychometric properties of the neuropsychological test battery was conducted to identify neuropsychological tests optimal for understanding cognitive aging. These tests were then used to characterize the effect of age on cognition. The first hypothesis was that older age would be associated with worse cognitive performance on all neuropsychological tests. The second hypothesis was that performance on tests of psychomotor speed and episodic memory would show the greatest impairment with increasing age.
Materials and Method
Participants Fig. 1 summarizes the sample screening process. All participants were aged between 60 and 85 and were selected from the cognitively normal (CN) group of the Australian Imaging Biomarkers and Lifestyle (AIBL) study (Ellis et al., 2009) . A consensus panel of geriatricians, neurologists, psychiatrists, and neuropsychologists determined clinical classifications after reviewing participant assessment results. Participants were classified as CN if their MMSE was greater than 24 and if they did not meet criteria for mild cognitive impairment (MCI; Winblad et al., 2004) or dementia (McKhann et al., 1984) . The AIBL study was approved by and complied with the regulations of three institutional research and ethics committees (St Vincent's Health, Austin Health, and Edith Cowan University). All participants provided written informed consent prior to participating in the study.
The AIBL study initially recruited participants via a media appeal, as well as via referrals from local physicians (for full details, see Ellis et al., 2009 ). Prior to enrollment, individuals were screened for significant medical and psychiatric history with a telephone interview. At this stage, individuals were excluded for a history of non-AD dementia, Parkinson's disease, schizophrenia, bipolar disorder, cancer (other than basal skin carcinoma) within the last 2 years, uncontrolled diabetes, current depression (indicated by a Geriatric Depression Scale score of >5), or current regular alcohol consumption exceeding two standard drinks per day for women or four per day for men. Individuals who satisfied criteria on the phone screen then attended the research unit to undergo detailed cognitive and neurological assessment (described in Ellis et al., 2009) .
At the research center, all individuals underwent cognitive and neurological assessment, provided a detailed medical history, completed assessment of vital signs (blood pressure, heart rate, body mass index [BMI]), and provided a blood sample. The study team also reviewed blood pathology results for all participants to identify any results indicative of systemic illness. The classification scheme of Bergman and colleagues (2007) was applied to these data. Individuals classified as having significant clinical CNS or systemic illness were excluded from this study. To ensure the absence of progressive CNS disease, neuropsychological and clinical data from the follow-up (up to 72 months) assessments were also reviewed. Neuropsychological data for individuals who had not completed at least one follow-up assessment, who progressed to meet clinical criteria for MCI or dementia, or who later withdrew from the AIBL study for reasons of ill health (e.g., cancer or stroke) were excluded from the current analyses.
Measures
Demographic and clinical characteristics. Age, gender, and education were self-reported by participants. Trained research assistants recorded medical history, assessed depression and anxiety symptoms using the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) , and administered the Wechsler Test of Adult Reading (WTAR; Wechsler, 2001 ) to estimate IQ.
Neuropsychological tests. The AIBL neuropsychological test battery assesses across the cognitive domains of executive function, episodic memory (immediate and delayed recall, and recognition), language, psychomotor speed and attention, and visuospatial functioning. The battery consists of 14 tests, including a combination of traditional paper and pencil neuropsychological tasks and computerized tasks from the CogState Brief Battery (CBB). Briefly, the CBB consisted of four tasks that require the participant to respond to playing card stimuli presented on the computer screen. These included the Detection (reaction time), Identification (choice reaction time), One Card Learning (visual recognition memory), and One Back (working memory) tasks (Lim et al., 2012) . Responses are made by pressing an external response button as quickly as possible following stimuli presentation and are in a Yes/No format. The complete neuropsychological battery, including the CBB, and administration procedures have been described in detail previously (Ellis et al., 2009; Lim et al., 2012) . Although many of these tests require multiple areas of cognition for optimal performance, each has been classified according to the main cognitive domain assessed (Lezak, 2012) . Meyers & Meyers, 1995) , and the One Card Learning task from the CBB (Lim et al., 2012) . Language was assessed by the 30-item Boston Naming Test (BNT; Saxton et al., 2000) ; Psychomotor Speed and Attention were assessed by the Digit Symbol Coding subtest of the WAIS-III (Wechsler, 1997) , the Stroop task Dots, Words, and Colors time scores (Strauss et al., 2006) , and the Detection and Identification tasks from the CBB (Lim et al., 2012) ; and Visuospatial Function was assessed by the Clock Drawing task (Strauss et al., 2006) and the Copy trial of the RCFT (Meyers & Meyers, 1995) .
Procedure
Participants fasted overnight prior to attending the research facility for clinical assessment. Written informed consent was first obtained, followed by collection of an 80-mL blood sample (used for genotyping and full blood analyses for medical assessment) and provision of breakfast. Participants then completed self-report questionnaires including demographic details and the HADS. Trained research assistants conducted a clinical interview and the neuropsychological assessment according to standardized protocols in a single session of approximately 120 min, followed by a medical examination including measurement of height, weight, blood pressure, heart rate, and abdominal circumference.
Study 1: Psychometric Characteristics of Neuropsychological Tests of Aging
The aim of the first study was to identify neuropsychological tests from the battery that produced optimal performance data to study age effects on cognition in healthy older adults.
Data Analysis
Data frequency distributions, skewness values, missing data cases and test-retest reliability over 18 months were generated for each neuropsychological test outcome measure. Where a neuropsychological test had multiple outcome measures each of these was examined independently. The process and results of data screening are summarized in Table 1 . Data frequency distributions were visually inspected to identify individual data points that were outliers. These data points were subsequently excluded from analyses for that measure. As there are no guidelines or recommendations for the classification of ceiling or floor effects in neuropsychological contexts, in the present study, a conservative criterion was defined where ceiling effects were classified to have occurred if ≥20% of the data were at the maximum possible score. Similarly, floor effects were determined to have occurred if ≥20% of the data were at the minimum possible score. Where data did not meet criteria for ceiling/floor effects, they were inspected for skew determined by visual inspection of data frequency distributions. Test-retest reliability was determined from two-way mixed effects intraclass correlations between baseline and 18-month follow-up test scores for each outcome measure. An intraclass correlation of >.50 was classified as indicating acceptable test-retest reliability (Koo & Li, 2016) . Remaining test outcome measures were then examined for redundancy by computing the correlations between outcome measures of the same cognitive domain derived from the same neuropsychological test. If two outcome measures from the same test showed a significant correlation, then one of the measures was subsequently removed. 
Results
Sample Characteristics. Demographic and clinical characteristics of the sample are summarized in Table 2 . There were slightly more women than men, average years of education was 12.5, IQ was estimated to be in the high average range, and levels of depression and anxiety symptoms were uniformly low. Additionally, vital signs of the selected sample were within subclinical ranges according to criteria from Bergman and colleagues (2007) ; systolic blood pressure M = 137.84 mmHg, SD = 15.52, diastolic blood pressure M = 79.07 mmHg, SD = 10.08, and BMI M = 26.60 kg/m 2 , SD = 4.19. The medical examination showed rates of systemic illness that were also low and in all cases were of subclinical severity and controlled medically; 22.1% hypertension, 6.5% diabetes, 2.0% skin cancer, 7.4% thyroid or parathyroid disease, 20.2% gastric complaints (primarily reflux), 49.2% arthritis (primarily osteoarthritis), 2.1% kidney disease, 1.4% liver disease, and 2.6% neurological complaint (primarily migraines, nerve pain, or benign tremor).
Test Psychometrics. Table 1 summarizes the results of the psychometric investigations for each of the neuropsychological outcome measures. Ceiling effects were identified for the Clock Drawing, CVLT-II Recognition, and BNT (Australian and U.S. versions) outcome measures, and a floor effect was identified for the False Positive score on the CVLT-II Recognition trial. Low test-retest reliability was identified for the Stroop Interference score, Fruit Furniture Switching score, and the Copy and Recognition scores on the RCFT. Additionally, Stroop Dots (r = .47) and Colors (r = .55) trials, and CVLT-II Short Delay trial (r = .78) were excluded as they were significantly correlated with other outcome measures from the same neuropsychological test.
Discussion
The exploratory analysis identified that many of the tests included in AIBL battery did not possess psychometric properties optimal for investigation of the effects of age on cognition. A battery of neuropsychological tests whose outcome data were not characterized by ceiling or floor effects, skew, or low reliability was identified (Table 3 ). This battery provided reliable measures of learning, immediate and delayed recall aspects of episodic memory, psychomotor speed, attention, and executive function that are appropriate and relevant for investigating age-related cognitive changes.
Study 2: The Effect of Age on Cognition
The aim of the second study was to characterize the effects of age on cognition in healthy older adults using the optimized battery of tests identified in Study 1.
Neuropsychological Outcome Measures
Selected tests did not show floor or ceiling effects, substantial distributional skew, and had acceptable test-retest reliability over 18 months. Table 3 summarizes the selected tests and corresponding cognitive domains. 
Data Analysis
To compare cognitive performance at different ages, participants were grouped into 5-year age bands (60-64, 65-69, 70-74, 75-79, and 80-84) . Scores on the WTAR were coded categorically according to descriptive IQ classification ranges (Low Average = 80-89, Average = 90-110, High Average = 111-120, Well-Above Average/Superior = 121-130; Wechsler, 1997) .
To determine the effect of age on cognition, a series of one-way analysis of variance (ANOVA) were conducted to compare mean performance across the five age groups on each of the selected neuropsychological outcome measures. Post hoc Dunnett tests were then conducted to compare the performance of the 60-to 64-year-old group with each of the other age groups. Finally, to determine the magnitude of the differences between age group performance on each of the outcome measures Hedges' g effect size measure of standardized mean difference was calculated to express the differences in SD units.
To explore the extent to which gender and IQ affected the relationship between age and cognitive performance, a series of multiple regressions were conducted. Age (entered as a continuous variable), gender, and WTAR categorical classification were entered as independent variables, and performance on each of the selected neuropsychological outcome measures entered as the dependent variable.
Results
Sample characteristics. The demographic and clinical characteristics of each age group are summarized in Table 2 . No significant differences were identified between the age groups for the proportion of women, level of education, estimated IQ, or levels of depression and anxiety symptoms. However, the 80-to 84-year-old group reported a slightly greater number of comorbid systemic illnesses than the other groups for their present health status on the medical history interview. Importantly, all systemic illnesses reported were of subclinical severity and controlled medically such that they were unlikely to affect cognitive function, hence analyses proceeded without any adjustment for covariates.
Effect of age on cognition. There was a significant effect of age on performance on each neuropsychological test except the Digit Span, FAS, One Card Learning, and Detection tests (see Table 3 for summary). Fig. 2 summarizes the results of the post hoc Dunnett tests and the magnitude of the differences in cognitive performance between the 60-to 64-year-old group and each of the other age groups. Age differences were not observed between the 60-to 64-year-old group and the 65-to 69-year-old group on any measure except Digit Symbol Coding, whereas the 75-79 and 80-84 year groups differed from the 60-to 64-year-old group on every measure except Identification and Logical Memory 1.
Effect of gender and IQ on age-related cognitive change. Multiple regression outcomes are summarized in Table 4 . Significant age effects were observed for almost all cognitive measures, with age accounting for the greatest variance in performance on Digit Symbol Coding, Stroop Words, CVLT-II Trials 1-5, RCFT Short and Long Delay, Fruit Furniture Total Score, One Back, and One Card Learning. Gender and IQ were also significant predictors of performance on most measures despite there being no differences between age groups on these demographic variables.
Discussion
The first hypothesis that older age would be associated with worse cognitive performance on all neuropsychological tests was supported partially. Moderate to large (Hedges' g = −0.34 to −1.34) age-related decreases in performance were observed for each neuropsychological test except the Digit Span, FAS, One Card Learning, and Detection tests (Fig. 2) . For tests where no age effect was identified the magnitude of differences between the youngest and oldest cohorts was small (Hedges' g = −0.01 to −0.36). As the Hedges' g effect size is equivalent to expressing impairment in terms of SD units, it can be compared directly with estimates of effects observed in prior studies of aging. Prior cross-sectional comparisons show age-related cognitive impairment that was systematically greater than that observed here (e.g., 0.5-1.5 SD unit decrease from age 60 to 80) for processing speed, memory, reasoning, and spatial ability (Schaie, 2005; van Hooren et al., 2007; Salthouse, 2010; Bonsang & Dohmen, 2015) . Furthermore, unlike in these previous studies of cognitive aging, the effect of age on cognitive performance was not consistent across all neuropsychological measures in the current study. One hypothesis is that the smaller and more specific effect of age on cognition observed in the current study was because this study took great care to exclude individuals with prodromal CNS disease and uncontrolled systemic illness, whereas most other studies have not. The small effect of age on cognition was confirmed in multivariate analyses assessing the extent to which age explained variance beyond gender and IQ. With these additional factors added to the models, the variance explained by age alone was very small (e.g., partial r = 0 to −.38; Table 4) . Similarly, education level and gender have been observed to have a substantial effect on cognitive performance independent of age effects, in a large community-based sample of older adults (aged 64-81 years) who did not have significant medical conditions and scored above 24 on the MMSE at enrollment (van Hooren et al., 2007) .
These data indicate that while complex psychomotor function, categorical fluency, verbal learning, and verbal and visual memory showed age-related impairment, in each case the magnitude of this was small when the contributions of gender and IQ were controlled statistically. Additionally, little or no age-related impairment was observed for working memory, phonemic fluency, learning visual information, and reaction time (Table 4) . Importantly, the effect of age on neuropsychological test performance was examined using tests with optimal psychometric properties and in a robust sample, without uncontrolled systemic medical illness and with a very low probability of prodromal CNS disease. Under these conditions, the effect of age on most aspects of cognition is small. The hypothesis that previous studies of cognitive aging have overestimated age-related cognitive impairment due to lack of precision in their definitions of healthy aging is theoretically consistent with the use of robust normative data in neuropsychological contexts. In these contexts, it is acknowledged that inclusion of individuals with suboptimal health, or indeed preclinical neurodegenerative disease, in normative samples will decrease the sensitivity of normal data ranges, derived from those samples, to identify true cognitive impairment in older people at risk of CNS disease. For example, inclusion of data from healthy older adults who later progress to dementia in normative estimates causes age-based estimates of cognitive performance to be lower and to have greater variability (Sliwinski et al., 1996; De Santi et al., 2008; Holtzer et al., 2008; Pedraza et al., 2010; Grober, Mowrey, Katz, Derby, & Lipton, 2015; Clark et al., 2016) . Thus, the development and application of robust normative data for neuropsychology is consistent with the hypothesis that in cross-sectional studies of aging the effects of age on cognition have been overestimated due to the inclusion of individuals who are not healthy.
The second hypothesis that performance on tests of psychomotor speed and episodic memory would show the greatest agerelated impairment was supported partially. Although the largest age-related impairment in cognition was observed for tests of psychomotor speed and episodic memory, these effects were not consistent across all neuropsychological tests within these domains (see Fig. 2 ). For example, when psychomotor speed was measured using the Digit Symbol Coding test the magnitude of difference between the youngest and oldest groups was substantial (Hedges' g = −1.34) in line with estimates derived from multiple studies using similar tests (van Hooren et al., 2007; Salthouse, 2010) . In comparison there were no, or only small (Hedges' g < −0.44), effects of age observed when psychomotor speed was measured with tests of simple or choice reaction time (i.e., Detection and Identification tasks). This is consistent with prior observations in a large population-based sample of older adults that there is stability of simple and choice reaction time over 13 years (Deary, Allerhand, & Der, 2009) . Similarly, for episodic memory the magnitude of difference between the 60-and 80-year-old groups was greatest for verbal word-list learning (Hedges' g = −0.97) and delayed recall (i.e., CVLT; Hedges' g = −0.71); while no, or only small, effects of age were observed for immediate and delayed recall of a short story (i.e., Logical Memory 1 and 2, Hedges' g < −0.45). Word-list learning and recall has been observed to be more sensitive to early cognitive changes associated with AD and PD than story recall (Rabin et al., 2009; Zahodne et al., 2011) . Thus, word-list learning may be more sensitive than story recall to changes in memory generally. One way to integrate the different effects of age on performance on different neuropsychological tests measuring the same cognitive domain is to consider these tests according to their complexity. For example, for the domain of psychomotor speed, age-related impairment was much greater for tests that required the integration of multiple cognitive operations (i.e., Digit Symbol Coding) than for measures that required only simple reflexive responses (i.e., Detection and Identification). Similarly, for episodic memory, age-related impairment in cognition was greater for tests with less contextual detail or support from gist (i.e., CVLT-II) than those where gist or semantic scaffolding supported encoding (i.e., Logical Memory). Thus, one hypothesis arising from this study is that age-related cognitive impairment is dependent not just on the domain of cognition, but also on the complexity of information processing required within that domain. Data from prior studies of CN adults support this hypothesis, reporting larger age effects for tasks that require more active and effortful processing than for simple tasks of the same cognitive process (van Hooren et al., 2007; Harris, Eckert, Ahlstrom, & Dubno, 2010; Frey, Mata, & Hertwig, 2015) .
General Discussion
When considered together, the results from this study suggest that age-related cognitive impairment may be of a smaller magnitude than reported previously (e.g., the relationship between age and speed, reasoning, and memory performance observed to be r = −.47, −.48, and −.43, respectively [Salthouse, 2004] , or about 1-1.5 SD difference in performance between 60 and 80 years old [Schaie, 2005; van Hooren et al., 2007; Salthouse, 2010; Bonsang & Dohmen, 2015] ). Prior cross-sectional studies may have overestimated the magnitude of cognitive impairment associated with aging due to their use of inclusion/exclusion criteria that lack precision, leading to the assessment of individuals with severe or uncontrolled systemic illness or even prodromal CNS disease, and the subsequent confounding of the effect of these health factors with aging. Notably, despite rigorous screening for cognitive and physical health prior to entry, approximately 10% of the AIBL sample, classified as CN initially, went on to be diagnosed with MCI or dementia over the next 72 months. A further 6% were identified to have had a vascular event, such as a stroke, or to develop a significant medical condition such as cancer (see Fig. 1 ). These rates of subclinical CNS and systemic disease are likely to be greater in other healthy aging samples that applied less rigorous criteria at screening than the AIBL study (e.g., Carlesimo et al., 1998; Bates & Wolbers, 2014; Bonsang & Dohmen, 2015; Brown, Johnson, Sohl, & Dumas, 2015) .
The results of this study also offer estimates of the normal effects of age on neuropsychological tests used commonly in decision-making about neurodegenerative disease, derived from a group of well-characterized older adults without uncontrolled systemic medical illness or prodromal CNS disease. Specifically, Table 3 provides estimates of group mean performance and variation for each age quintile between 60 and 84 years. These estimates of the effect of aging on cognition, developed from a cognitively healthy group and based on neuropsychological tests that have optimal characteristics for measurement of cognitive change, may be of use to neuropsychologists engaged in clinical assessment and diagnosis. The methods used to refine these estimates by excluding data from individuals who had severe or uncontrolled systemic illness or prodromal CNS disease are equivalent to those used in the generation of robust neuropsychological data. Thus, the age-based estimates of normal cognitive performance presented here could facilitate greater sensitivity to cognitive impairment in older adults at risk of CNS injury, disease, or disorder than normative data used currently (De Santi et al., 2008; Grober et al., 2015; Clark et al., 2016) .
There are some caveats for the interpretation of the results of the present study. First, this is an experimental convenience sample and as such may not be representative of the broader aging population. The rigorous inclusion criteria applied here ensured the physical and cognitive health of the sample and rendered it ideal for developing models of cognitive aging, independent of the effects of other health or social factors. However, one issue arising from the methodology applied here to identify healthy aging, as well as acceptance of robust normative samples in neuropsychology more generally, is whether such samples should be considered to reflect normal aging, or whether they should be defined as super aging or successful aging. Although this idea is compelling, there remains an absence of any clear neuropsychological definition or criteria for super or successful aging. Therefore, in this context we suggest to focus on the concept of robust estimates of cognitive aging, until such criteria for super or successful aging are developed. Thus, the data averages and ranges developed from the current sample (Table 3 ) may be of clinical utility to neuropsychologists. Second, it is known that systemic illness (e.g., hypertension, dyslipidaemia, or diabetes) occurring during early-or mid-life may affect CNS function and cognitive ability in later life (van Vliet, 2012; Gottesman et al., 2014; Rawlings et al., 2014) . Although these effects have not been accounted for in the present study, it is unlikely that they will have substantially influenced estimates of age-related cognitive impairment in the present sample as all individuals provided a detailed medical history and free universal healthcare and subsidized medications have been available in Australia for the past 60 years. Third, the selection of neuropsychological tests in the present study was constrained by the aims of the AIBL study rather than by theoretical models of aging. However, the tests selected were chosen for their sensitivity to dementia, and therefore they will be familiar and commonly used by neuropsychologists. Finally, the analyses used to consider the effect of age on cognitive function in the present study were cross-sectional design. Accordingly, no inferences regarding change in cognitive function over time can be made. Additionally, it is known that estimates of the effect of age on cognition based on studies with cross-sectional designs can be influenced by cohort effects (Schaie, 2005; Salthouse, 2014) . These reflect variability in samples due to age-related differences in environmental factors such as access to healthcare and education. In the current study, we have sought to mitigate the potential for cohort effects to bias results by selecting IQ rather than education to characterize the premorbid ability of the sample, and conducting the research in a context where there has been universal free healthcare access for the past 60 years. Although these aspects of the sample may not entirely overcome cohort effects, they do minimize the major effects. However, further investigation of cognitive aging in the absence of prodromal CNS disease and severe systemic illness with prospective design is now necessary.
Conclusion
These caveats notwithstanding, the results from the present study provide an important indication of the nature and magnitude of age-related cognitive impairment in healthy older individuals. Notably, the impact of aging does not appear to be ubiquitous across cognitive domains, but in fact may be limited to higher order complex functions and of a smaller magnitude occurring later than previously reported. In terms of clinical decision-making, the estimates of age-related cognitive impairment from the present study provide objective reference ranges of performance on specific neuropsychological tests for very healthy older adults (see Table 3 for normative means and SD derived for these). Thus, cognitive impairment falling within these ranges likely reflects true cognitive aging. 
